Drug Profile
Setanaxib - GenKyoTex
Alternative Names: GKT 831; GKT-137831Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator GenKyoTex
- Developer Calliditas Therapeutics; GenKyoTex; University of California, Davis; University of California, San Diego
- Class Amines; Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Chlorinated hydrocarbons; Eye disorder therapies; Ketones; Osteoporosis therapies; Pyrazoles; Pyridines; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action NOX1 protein inhibitors; NOX4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Primary biliary cirrhosis
- Phase II Diabetic nephropathies; Hereditary nephritis; Idiopathic pulmonary fibrosis; Squamous cell cancer
- No development reported Hepatic fibrosis; Non-alcoholic steatohepatitis; Systemic scleroderma
- Discontinued Atherosclerosis; Bone disorders; Eye disorders
Most Recent Events
- 11 Apr 2024 Calliditas Therapeutics receives notice of allowance for Setanaxib in USA
- 30 Nov 2023 Phase-II clinical trials in Hereditary nephritis (PO)
- 05 Oct 2023 The European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the company's application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome